Scilex Holding Company’s Post

This is an important milestone in our path towards unlocking the value of SP-102 (SEMDEXA™). Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. (Nasdaq: DECA) (“SPAC”) announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur of up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected cash on hand at closing of up to $40 million depending on the number of SPAC shares that are redeemed prior to the completion of the business combination.

#News for #Investors and #Media. #Hikma announces plans to expand its Injectables commercial portfolio, pipeline, manufacturing capabilities and R&D by acquiring select assets from Xellia Pharmaceuticals. This supports the long-term growth of our Injectables business. Riad Mishlawi, CEO, commented: "Hikma has grown to become a top-three US supplier of sterile injectable medicines thanks to our strong record of successfully making value-enhancing acquisitions like this one. This acquisition will add significant scale to our US operations and will enhance our US injectable manufacturing capabilities and portfolio by adding complex technologies. I am confident that this transaction will deliver significant future value to our Injectables business, supporting growth over the medium term.” Read the press release: https://brnw.ch/21wKN9K

Hikma Pharmaceuticals to buy some "assets" from Xellia Pharmaceuticals A good deal! Here is why.. The bought #assets include: * a manufacturing facility with FDA stamp. ( Xellia paid 200 millions at least to renovate this plant to get fda clarence) * R&D center in Croatia * 8 approved, already marketed products ( 85 million expected sales) and 11 #pipeline products. Remarks, * The total #cost of this deal is up to 185 million. * The deal includes the new "premix bag" #products.. ready to inject products preferred by doctors in emergency. * Xellia managed to get fda commercial approval for the mentioned site 8 months ago. And it is one of the few who has this #technology. So it's logical to think that Hikma picked injectables as a #strategy to get pioneer products. Products that are slightly better than what is available. Small, slow steps toward achieving the #objective... timely strategy but with the minimal #risks.. You have to respect that.. Congratulations for Hikma. Approved once more that it operates in a different league than the rest.

Inovio Pharmaceuticals ( $INO ) HYPERACTIVELY RESPONDS TO MARKET TRENDS with average analyst rating of BUY from 5 analysts: The company reported the last year's revenue of 832.01 M. Reported Net Loss for the year was (135.12 B) with loss before taxes, overhead, and interest of (177.39 M). Inovio Pharmaceuticals preserves 122.59 m of current valuation. Inovio Pharmaceuticals is trading at 10.18. This is 12.74 percent increase. Today highest was 10.74. https://lnkd.in/ehJ_PJ7T #hotstocks #investing #trading

Beximco Pharmaceuticals' FY23-24 Q3: Profits Surge by 51%! A robust performance fueled by soaring sales and savvy cost management. Profit jumps to Tk 136 crore, up from Tk 90 crore last year. Earnings per share (EPS) rise to Tk 3.06. Sales climb by 15% to Tk 1,098 crore. Beximco Pharmaceuticals continues its upward trajectory in the pharmaceutical landscape. #EmergingTiger #BeximcoPharma #ProfitSurge #FY23-24Q3 #BusinessNews

Sensex Today | Stock Market LIVE Updates: B&K Securities has maintained its ‘Buy’ rating with Target Price of Rs. 770 (CMP- Rs. 622) for Suven Pharmaceuticals as it expect revenue of the company to double at combined sales (Suven + Cohance) over the next four-five years. The company remains top mid-cap pick in brokerage firm’s universe.

According to a report by Fierce Pharma, pharmaceutical companies invested US$115.8 billion in business acquisitions in 2023, exceeding the previous amounts of 2022, 2021, and 2020. - #pharma #markettrends

Baker McKenzie successfully represented Genomma in the divestment of its stake in Mexican pharmaceutical company Marzam. The transaction is part of Genomma's strategy to sell non-core assets and focus on its main brands. Learn more about the deal https://lnkd.in/eT9ACdSZ.

04 Ranking list of pharmaceutical companies with sales growth in 2024 Although Novo Nordisk can only temporarily be at the bottom of the list in terms of sales, its sales growth ranks first (Figure 4). With the strong momentum of Ozempic and Wegovy, #Novo Nordisk will generate nearly $8 billion in additional revenue in 2024. Eli Lilly's revenue growth will reach nearly $5 billion, ranking second.

During the January-March quarter of FY 2023-24, Beximco Pharmaceuticals Ltd. reported a significant 51 percent increase in profits compared to the same period last year, driven by robust sales and effective cost management strategies. 👉 The company's profit climbed to Tk 136 crore, up from Tk 90 crore recorded in the corresponding quarter of the previous fiscal year. 👉 Consequently, earnings per share (EPS) for Beximco Pharmaceuticals increased to Tk 3.06 at the end of March, up from Tk 2.13 at the end of the same month last year. 👉 Additionally, the company saw a 15 percent year-on-year growth in sales, reaching Tk 1,098 crore in the third quarter of FY24. Read more to generate a fully informed opinion: https://lnkd.in/g_dc2svz #Beximco #BeximcoPharma #Brandupdates #bangladesh #markedium